Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Oncology (NASDAQ:CTOR) reported its fiscal Q3 2025 results and provided updates on its commercial launch preparations for LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma. The company secured $12.5 million in financing during Q3, with an additional $9 million raised in July 2025, to support LYMPHIR's market introduction planned for Q4 2025.
Financial results showed a net loss of $5.4 million ($0.08 per share), compared to $4.8 million ($0.07 per share) in Q3 2024. R&D expenses decreased to $938,000 from $1.1 million year-over-year, while G&A expenses increased to $1.9 million from $1.5 million. The company reported $112 in cash with 71,552,402 common shares outstanding as of June 30, 2025.
Positive
- Successful fundraising of $21.5 million total ($12.5M in Q3 + $9M in July) to support LYMPHIR launch
- LYMPHIR commercial launch preparations on track for Q4 2025
- Distribution service agreements secured with leading global providers
- Reduction in R&D expenses by 14.7% year-over-year
Negative
- Increased net loss to $5.4 million from $4.8 million year-over-year
- G&A expenses increased by 26.7% to $1.9 million
- Extremely low cash position of $112 as of June 30, 2025
- Higher stock-based compensation expense at $2.1 million
Insights
Citius Oncology's cash position improved through financing rounds as it prepares for Q4 2025 LYMPHIR launch, though quarterly losses increased year-over-year.
Citius Oncology (NASDAQ: CTOR) is approaching a critical inflection point with its lead product LYMPHIR for cutaneous T-cell lymphoma, planning commercial availability in Q4 2025. The company has strategically raised capital to fund pre-launch activities, securing
Looking at the quarterly financials, R&D expenses decreased to
The net loss widened to
The reported cash position of just
The successful transition from development to commercialization will be critical for Citius Oncology's financial trajectory, particularly as expenditures are likely to increase further with the upcoming product launch while revenue generation remains on the horizon.
LYMPHIR commercial availability planned for the fourth quarter of 2025
"Citius Oncology is in the final stages of preparation for the
FISCAL THIRD QUARTER 2025 FINANCIAL HIGHLIGHTS:
- On July 17, 2025, Citius Oncology completed a public offering generating net proceeds of approximately
$7.4 million - R&D expenses were
$938,000 $1.1 million - G&A expenses were
$1.9 million $1.5 million - Stock-based compensation expense was
$2.1 million $2.0 million - Net loss was
$5.4 million $0.08 $4.8 million $0.07 - As of June 30, 2025, the Company had
$112 $10.5 million
For a complete discussion of our financial results, please refer to our Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed today with the SEC and available at www.sec.gov.
About Citius Oncology, Inc.
Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our need for substantial additional funds and our ability to raise additional money to fund our operations beyond September 2025 and for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services, and any of our other product candidates that may be approved by the FDA; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our product candidates and the acceptance thereof by any market; our ability to maintain compliance with Nasdaq's continued listing standards; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; uncertainties relating to preclinical and clinical testing; market, economic and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, Citius Oncology's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 12, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
-- Financial Tables Follow –
CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
June 30, | September 30, | |||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 112 | $ | 112 | ||||
Inventory | 17,208,967 | 8,268,766 | ||||||
Prepaid expenses | 1,100,000 | 2,700,000 | ||||||
Total Current Assets | 18,309,079 | 10,968,878 | ||||||
Other Assets: | ||||||||
In-process research and development | 73,400,000 | 73,400,000 | ||||||
Total Other Assets | 73,400,000 | 73,400,000 | ||||||
Total Assets | $ | 91,709,079 | $ | 84,368,878 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 8,667,419 | $ | 3,711,622 | ||||
License payable | 28,400,000 | 28,400,000 | ||||||
Accrued expenses | 8,458,554 | — | ||||||
Due to related party | 7,464,362 | 588,806 | ||||||
Total Current Liabilities | 52,990,335 | 32,700,428 | ||||||
Deferred tax liability | 2,520,720 | 1,728,000 | ||||||
Note payable to related party | 3,800,111 | 3,800,111 | ||||||
Total Liabilities | 59,311,166 | 38,228,539 | ||||||
Stockholders' Equity: | ||||||||
Preferred stock - | — | — | ||||||
Common stock - | 7,155 | 7,155 | ||||||
Additional paid-in capital | 91,434,058 | 85,411,771 | ||||||
Accumulated deficit | (59,043,300) | (39,278,587) | ||||||
Total Stockholders' Equity | 32,397,913 | 46,140,339 | ||||||
Total Liabilities and Stockholders' Equity | $ | 91,709,079 | $ | 84,368,878 | ||||
CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2025 AND 2024 (Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
June 30, | June 30, | June 30, | June 30, | |||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenues | $ | — | $ | — | $ | — | $ | — | ||||||||
Operating Expenses | ||||||||||||||||
Research and development | 938,277 | 1,131,439 | 5,342,198 | 3,628,900 | ||||||||||||
General and administrative | 1,881,447 | 1,540,411 | 7,446,753 | 4,443,899 | ||||||||||||
Stock-based compensation – general and administrative | 2,125,237 | 1,957,000 | 6,022,287 | 5,831,000 | ||||||||||||
Total Operating Expenses | 4,944,961 | 4,628,850 | 18,811,238 | 13,903,799 | ||||||||||||
Operating Loss | (4,944,961) | (4,628,850) | (18,811,238) | (13,903,799) | ||||||||||||
Interest expense | 160,755 | — | 160,755 | — | ||||||||||||
Loss before Income Taxes | (5,105,716) | (4,628,850) | (18,971,993) | (13,903,799) | ||||||||||||
Income tax expense | 264,240 | 144,000 | 792,720 | 432,000 | ||||||||||||
Net Loss | $ | (5,369,956) | $ | (4,772,850) | $ | (19,764,713) | $ | (14,335,799) | ||||||||
Net Loss Per Share - Basic and Diluted | $ | (0.08) | $ | (0.07) | $ | (0.28) | $ | (0.21) | ||||||||
Weighted Average Common Shares Outstanding | ||||||||||||||||
Basic and diluted | 71,552,402 | 67,500,000 | 71,552,402 | 67,500,000 | ||||||||||||
CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED JUNE 30, 2025 AND 2024 (Unaudited) | ||||||||
2025 | 2024 | |||||||
Cash Flows From Operating Activities: | ||||||||
Net loss | $ | (19,764,713) | $ | (14,335,799) | ||||
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
Stock-based compensation expense | 6,022,287 | 5,831,000 | ||||||
Deferred income tax expense | 792,720 | 432,000 | ||||||
Changes in operating assets and liabilities: | ||||||||
Inventory | (8,940,201) | - | ||||||
Prepaid expenses | 1,600,000 | (2,271,920) | ||||||
Accounts payable | 4,955,797 | (1,289,045) | ||||||
Accrued expenses | 8,458,554 | 185,930 | ||||||
Due to related party | 6,875,556 | 11,447,834 | ||||||
Net Cash Provided By Operating Activities | - | - | ||||||
Net Change in Cash and Cash Equivalents | - | - | ||||||
Cash and Cash Equivalents – Beginning of Period | 112 | - | ||||||
Cash and Cash Equivalents – End of Period | $ | 112 | $ | - | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-third-quarter-2025-financial-results-and-provides-business-update-302528107.html
SOURCE Citius Oncology, Inc.
FAQ
When will Citius Oncology (CTOR) launch LYMPHIR commercially?
How much capital did Citius Oncology (CTOR) raise in Q3 2025 and July 2025?
What was Citius Oncology's (CTOR) net loss per share in Q3 2025?
How much cash does Citius Oncology (CTOR) have as of June 30, 2025?
What is LYMPHIR and what is it used for?
